Immunomedics’ decades-long comeback continues
After more than 35 years of internal strife, scientific setbacks, and dwindling investor interest, Immunomedics has demonstrated that its long-delayed drug had a dramatic effect on a particularly aggressive form of breast cancer.
As STAT’s Adam Feuerstein reports, the company’s therapy reduced the risk of tumor progression or death by 59% compared to chemotherapy in a study involving 500 patients with advanced, triple-negative breast cancer, a disease with few options for treatment.
The results should support a full approval for Immunomedics’ drug, which won a conditional nod in April, and bring some vindication for a company that has weathered years of up-and-down development.
Read more.
As STAT’s Adam Feuerstein reports, the company’s therapy reduced the risk of tumor progression or death by 59% compared to chemotherapy in a study involving 500 patients with advanced, triple-negative breast cancer, a disease with few options for treatment.
The results should support a full approval for Immunomedics’ drug, which won a conditional nod in April, and bring some vindication for a company that has weathered years of up-and-down development.
Read more.
No hay comentarios:
Publicar un comentario